Envestnet Asset Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Envestnet Asset Management’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-157	Closed	-$122K	–	4010
2023 Q1	$122K	Sell	157 -46	-23%	-$34K	﹤0.01%	3768
2022 Q4	$61K	Buy	203 +115	+131%	+$48.6K	﹤0.01%	3854
2022 Q3	$44K	Buy	88 +28	+47%	+$17.1K	﹤0.01%	3817
2022 Q2	$34K	Buy	60 +2	+3%	+$1.67K	﹤0.01%	3850
2022 Q1	$75K	Sell	58 -14	-19%	-$15.5K	﹤0.01%	3831
2021 Q4	$82K	Buy	72 +34	+89%	+$46.6K	﹤0.01%	3778
2021 Q3	$59K	Sell	38 -55	-59%	-$88.1K	﹤0.01%	3623
2021 Q2	$184K	Buy	93 +67	+258%	+$123K	﹤0.01%	3507
2021 Q1	$48K	Buy	+26	New	+$57K	﹤0.01%	3451

Other funds holding HEPA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Envestnet Asset Management's HEPA Position: Q2 2023 in Review

Envestnet Asset Management sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 157 shares — an estimated $122K sold.

Envestnet Asset Management first reported a position in HEPA in Q1 2021 and held it in 9 quarters. The position peaked at $184K in Q2 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

Envestnet Asset Management reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Envestnet Asset Management sold 157 Hepion Pharmaceuticals shares in Q2 2023, an estimated $122K.
Envestnet Asset Management first reported a position in Hepion Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Envestnet Asset Management's Hepion Pharmaceuticals position peaked at $184K in Q2 2021.
16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on Envestnet Asset Management's 13F filing for Q2 2023, filed 4 Aug 2023.